English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background  Although many biomarkers have been reported for detecting glioma, the prognosis for the disease remains poor, and therefore, new biomarkers need to be identified.  GNG5 , which is part of the G-protein family, has been associated with different malignant tumors, though the role of  GNG5  in glioma has not been studied. Therefore, we aimed to identify the relationship between  GNG5  and glioma prognosis and identify a new biomarker for the diagnosis and treatment of gliomas.    Methods  We used data on more than a thousand gliomas from multiple databases and clinical data to determine the expression of  GNG5  in glioma. Based on clinical data and CGGA database, we identified the correlation between  GNG5  and multiple molecular and clinical features and prognosis using various analytical methods. Co-expression analysis and GSEA were performed to detect  GNG5 -related genes in glioma and possible signaling pathways involved. ESTIMATE, ssGSEA, and TIMER were used to detect the relationship between  GNG5  and the immune microenvironment. Functional experiments were performed to explore the function of  GNG5  in glioma cells.    Results   GNG5  is highly expressed in gliomas, and its expression level is positively correlated with pathological grade, histological type, age, and tumor recurrence and negatively correlated with isocitrate dehydrogenase mutation, 1p/19 co-deletion, and chemotherapy. Moreover,  GNG5  as an independent risk factor was negatively correlated with the overall survival time. GSEA revealed the potential signaling pathways involved in  GNG5  function in gliomas, including cell adhesion molecules signaling pathway. The ssGSEA, ESTIMATE, and TIMER based analysis indicated a correlation between  GNG5  expression and various immune cells in glioma. In vivo and in vitro experiments showed that  GNG5  could participate in glioma cell proliferation and migration.    Conclusions  Based on the large data platform and the use of different databases to corroborate results obtained using various datasets, as well as in vitro and in vivo experiments, our study reveals for the first time that  GNG5 , as an oncogene, is overexpressed in gliomas and can inhibit the proliferation and migration of glioma cells and lead to poor prognosis of patients. Thus,  GNG5  is a potential novel biomarker for the clinical diagnosis and treatment of gliomas.    Supplementary Information  The online version contains supplementary material available at 10.1186/s12935-021-01935-7.

GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma